About this trial
At present, there are 290 million cardiovascular patients in China, including 11 million patients with coronary heart disease. Remote ischemic preconditioning(RIPC) may play an effective endogenous cardiac protection.This study will explore whether long-term use of RIPC in patients with AMI after PCI and non interventional therapy can reduce the incidence of major adverse cardiovascular cerebrovascular events(MACCE) and improve clinical outcomes and long-term prognosis.
Eligibility criteria
Qualifiers
Patients with acute myocardial infarction were diagnosed in accordance with the criteria of the "Global Unified Definition of Fourth Myocardial Infarction"
Disqualifiers
The patients could not tolerate RIPC or RIPerC
Aortic dissection, coronary artery aneurysm, coronary artery fistula and other systemic organic diseases
The uncontrolled systolic blood pressure and diastolic blood pressure of severe hypertension were 180 mmHg and 120 mmHg respectively
severe liver dysfunction (bilirubin > 20 mmol / L, prothrombin time > 2.0 ratio)
Trial design
Treatments tested in this trial
- RIPerC
- RIPC